Growing Number of Patients With Advanced Liver Disease Will Take the Hepatitis C Virus Drug Market to $10 Billion In 2013

[Guest guest]

Growing Number of Patients With Advanced Liver Disease Will Take the

Hepatitis C Virus Drug Market to $10 Billion In 2013

Experts Disagree About Which Patients Are Best Suited For Treatment,

According

to a New Study from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, Inc., one

of

the world's leading research and advisory firms focusing on pharmaceutical

and

health care issues, finds that the growing number of patients with advanced

liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10

billion in 2013. HCV disease burden is expected to rise during the next ten

years because of a maturing HCV population that has been infected for more

than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled Hepatitis C Virus also finds that

experts

disagree about which patients are best suited for treatment given that HCV

does not place all infected persons at risk of significant morbidity or

mortality.

" Some experts contend that the goal of anti-HCV therapy is to prevent

cirrhosis and hepatocellular carcinoma, " says LaBonte, Ph.D., analyst

at

Decision Resources. " Based on these criteria, patients with normal serum ALT

levels and who therefore are not at risk of advanced liver disease do not

require treatment. These experts also maintain that the safety and efficacy

of

current therapies is not sufficient to warrant treatment in this patient

group. Other experts believe that patients with mild disease are more likey

to

respond to current therapies, and they say that the prevention of HCV

transmission, improvement in quality of life, and improvement of symptoms

are

important considerations when determining whether or not to treat patients

with normal serum ALT levels. "

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-

impacting factors and analyzes the commercial outlook for drugs in research

and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world

leader in

research publications, advisory services, and consulting designed to help

clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Marshall

Decision Resources, Inc.

781-296-2563

emarshall@...

SOURCE Decision Resources, Inc.

Web Site: http://www.decisionresources.com

[Guest guest]

Growing Number of Patients With Advanced Liver Disease Will Take the

Hepatitis C Virus Drug Market to $10 Billion In 2013

Experts Disagree About Which Patients Are Best Suited For Treatment,

According

to a New Study from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, Inc., one

of

the world's leading research and advisory firms focusing on pharmaceutical

and

health care issues, finds that the growing number of patients with advanced

liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10

billion in 2013. HCV disease burden is expected to rise during the next ten

years because of a maturing HCV population that has been infected for more

than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled Hepatitis C Virus also finds that

experts

disagree about which patients are best suited for treatment given that HCV

does not place all infected persons at risk of significant morbidity or

mortality.

" Some experts contend that the goal of anti-HCV therapy is to prevent

cirrhosis and hepatocellular carcinoma, " says LaBonte, Ph.D., analyst

at

Decision Resources. " Based on these criteria, patients with normal serum ALT

levels and who therefore are not at risk of advanced liver disease do not

require treatment. These experts also maintain that the safety and efficacy

of

current therapies is not sufficient to warrant treatment in this patient

group. Other experts believe that patients with mild disease are more likey

to

respond to current therapies, and they say that the prevention of HCV

transmission, improvement in quality of life, and improvement of symptoms

are

important considerations when determining whether or not to treat patients

with normal serum ALT levels. "

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-

impacting factors and analyzes the commercial outlook for drugs in research

and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world

leader in

research publications, advisory services, and consulting designed to help

clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Marshall

Decision Resources, Inc.

781-296-2563

emarshall@...

SOURCE Decision Resources, Inc.

Web Site: http://www.decisionresources.com

[Guest guest]

Growing Number of Patients With Advanced Liver Disease Will Take the

Hepatitis C Virus Drug Market to $10 Billion In 2013

Experts Disagree About Which Patients Are Best Suited For Treatment,

According

to a New Study from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, Inc., one

of

the world's leading research and advisory firms focusing on pharmaceutical

and

health care issues, finds that the growing number of patients with advanced

liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10

billion in 2013. HCV disease burden is expected to rise during the next ten

years because of a maturing HCV population that has been infected for more

than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled Hepatitis C Virus also finds that

experts

disagree about which patients are best suited for treatment given that HCV

does not place all infected persons at risk of significant morbidity or

mortality.

" Some experts contend that the goal of anti-HCV therapy is to prevent

cirrhosis and hepatocellular carcinoma, " says LaBonte, Ph.D., analyst

at

Decision Resources. " Based on these criteria, patients with normal serum ALT

levels and who therefore are not at risk of advanced liver disease do not

require treatment. These experts also maintain that the safety and efficacy

of

current therapies is not sufficient to warrant treatment in this patient

group. Other experts believe that patients with mild disease are more likey

to

respond to current therapies, and they say that the prevention of HCV

transmission, improvement in quality of life, and improvement of symptoms

are

important considerations when determining whether or not to treat patients

with normal serum ALT levels. "

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-

impacting factors and analyzes the commercial outlook for drugs in research

and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world

leader in

research publications, advisory services, and consulting designed to help

clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Marshall

Decision Resources, Inc.

781-296-2563

emarshall@...

SOURCE Decision Resources, Inc.

Web Site: http://www.decisionresources.com

[Guest guest]

Growing Number of Patients With Advanced Liver Disease Will Take the

Hepatitis C Virus Drug Market to $10 Billion In 2013

Experts Disagree About Which Patients Are Best Suited For Treatment,

According

to a New Study from Decision Resources

WALTHAM, Mass., April 20 /PRNewswire/ -- Decision Resources, Inc., one

of

the world's leading research and advisory firms focusing on pharmaceutical

and

health care issues, finds that the growing number of patients with advanced

liver disease will fuel a rise of the hepatitis C virus (HCV) market to $10

billion in 2013. HCV disease burden is expected to rise during the next ten

years because of a maturing HCV population that has been infected for more

than 20 years, the amount of time it takes for morbidity from HCV to emerge.

The new Pharmacor study entitled Hepatitis C Virus also finds that

experts

disagree about which patients are best suited for treatment given that HCV

does not place all infected persons at risk of significant morbidity or

mortality.

" Some experts contend that the goal of anti-HCV therapy is to prevent

cirrhosis and hepatocellular carcinoma, " says LaBonte, Ph.D., analyst

at

Decision Resources. " Based on these criteria, patients with normal serum ALT

levels and who therefore are not at risk of advanced liver disease do not

require treatment. These experts also maintain that the safety and efficacy

of

current therapies is not sufficient to warrant treatment in this patient

group. Other experts believe that patients with mild disease are more likey

to

respond to current therapies, and they say that the prevention of HCV

transmission, improvement in quality of life, and improvement of symptoms

are

important considerations when determining whether or not to treat patients

with normal serum ALT levels. "

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market-

impacting factors and analyzes the commercial outlook for drugs in research

and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com) is a world

leader in

research publications, advisory services, and consulting designed to help

clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be

trademarks or registered trademarks of their respective holders.

For more information, contact:

Marshall

Decision Resources, Inc.

781-296-2563

emarshall@...

SOURCE Decision Resources, Inc.

Web Site: http://www.decisionresources.com